08:42 AM EDT, 08/27/2025 (MT Newswires) -- Azitra ( AZTR ) said Wednesday that it has dosed the first patient in a phase 1/2 clinical study evaluating its ATR04-484 biotherapeutic candidate intended to treat skin rashes associated with epidermal growth factor receptor inhibitors.

Shares of the company were up 90% in recent Wednesday premarket activity.

Epidermal growth factor receptor inhibitors are targeted cancer therapies used in treatments for non-small cell lung cancer and colorectal cancer, but can cause dermatologic toxicities like papulopustular rashes, the company said.

The company said previously that ATR-04 received fast-track designation from the US Food and Drug Administration in September 2024.